Precise targeting of HIV broadly neutralizing antibody precursors in humans

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01<sub>B</sub>, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

Authors

Institutions

Publication Details

Journal
Science
Published
2025-05-15
DOI
https://doi.org/10.1126/science.adv5572
Citations
28
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
29.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Precise targeting of HIV broadly neutralizing antibody precursors in humans

Sheetal Sawant, Adrian B. McDermott, Kellie J. MacPhee, David C. Montefiori et al.
28 citations
Science
HIV Research and Treatment
29.02
article

Precise targeting of HIV broadly neutralizing antibody precursors in humans

Sheetal Sawant, Adrian B. McDermott, Kellie J. MacPhee, David C. Montefiori, Ian A. Wilson, David Joseph Diemert, Alison Benner, Kelli Greene, Martina Turroja, Weiwei Wu, Swastik Phulera, Marit J. van Gils, Zahra Rikhtegaran Tehrani, Burc Barin, Richard A. Koup, John P. Moore, Isabel Regadas, Stephen M. Kaminsky, Martin Corcoran, Marina Caskey, Aimee Desrosiers, Catarina Mendes Silva, Suprabhath Gajjala, Mukundhan Ramaswami, Jacqueline van Rijswijk, Georgia D. Tomaras, Judith A. Burger, Sashank Agrawal, Anila Yasmeen, Tom P. L. Bijl, Albert Cupo, Emma I. M. M. Reiss, Annelou van der Veen, J Kim, Sarah F. Andrews, Gabriel Ozorowski, Jan M. Prins, Godelieve J. de Bree, Joey H. Bouhuijs, Per Johan Klasse, Farhad Rahaman, Jennifer A. Bohl, Dagna Laufer, Ronald Derking, Karlijn van der Straten, Drienna Holman, Michelle J. Klouwens, Nicole L. Yates, Hongmei Gao, David M. Brown, Marinus H. Liesdek, Neeltje A. Kootstra, Andrew B. Ward, Alicia Sato, Tom G. Caniels, Rhianna Bronson, Angela Lombardo, Wen-Hsin Lee, Jonne L. Snitselaar, Gunilla B. Karlsson Hedestam, Elissa Malkin, Yung-Wen Liu, Rogier W. Sanders, Madhu Prabhakaran, Katrina G. Millard, Kurt T. Randall, Ollivier Hyrien, Shiyu Zhang, Jalen Jean-Baptiste, Isabel J. L. Baken, Jeffrey M. Bethony, Andrew Sullivan, Michael O. Duff, Margaret Meller, Vince Philiponis, Lindsey Mwoga, Solmaz Shotorbani
article en
28 citations

Abstract

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01<sub>B</sub>, induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

ScienceVol. 389(6759)
Scripps Research Institute (US), National Institutes of Health (US), International AIDS Vaccine Initiative (US), George Washington University (US), Cornell University (US), Foundation for the National Institutes of Health (US), Karolinska Institutet (SE), Fred Hutch Cancer Center (US), Amsterdam Neuroscience (NL), Emmes (United States) (US), Duke Medical Center (US), National Institute of Allergy and Infectious Diseases (US), Amsterdam University Medical Centers (NL), Weill Cornell Medicine (US), Rockefeller University (US), University of Amsterdam (NL)
U.S. Department of Energy, Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, Vaccine Research Center, Vetenskapsrådet, National Institutes of Health, Office of Science, Brookhaven National Laboratory, NHLBI Division of Intramural Research
Good health and well-being
Openalex Percentile: Top 0%
HIV Research and Treatment
29.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.